BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | A205806 | DR REDDYS LABORATORIES SA
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
INDIVIOR INC. et al v. DR. REDDY'S LABORATORIES S.A. et al 1 patentANDA 205299, 205806buprenorphine hydrochloride and naloxone hydrochloride | D.N.J. | 2017-09-14 | Terminated 2022-06-28 | — |
Indivior Inc. et al v. Teva Pharmaceuticals USA, Inc. 5 patentsANDA 205299, 205806buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2016-03-21 | Terminated 2019-09-05 | — |
Indivior, Inc. et al v. Dr. Reddy's Laboratories S.A., et al. 3 patentsANDA 205806buprenorphine hydrochloride and naloxone hydrochloride | D. Del. | 2014-12-02 | Terminated 2019-09-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$4.20
per ea
Lowest NADAC/Unit
$2.27
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 43598058130BUPRENORPHINE-NALOXONE 12-3 MG SL FILM | $4.20 | EA | Generic | — | 2026-06-17 |
| 43598058030BUPRENORPHINE-NALOXONE 4-1 MG SL FILM | $2.27 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.